Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.

Pain Clinical Trial

Official title:

Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02437669
• Other study ID #: AAAP5709
• Status: Completed
• Phase: Phase 2
• Start date: May 2015
• Est. completion date: April 2018

Study information

• Verified date: May 2019
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intranasal hydromorphone has been shown to be effective in reducing acute pain in adults. It has not been previously studied in children, but may be a viable option for effectively and safely reducing pain in children by administering an analgesic by the intranasal route.

This study will be a prospective, open-label pilot study of intranasal hydromorphone in children with moderate to severe acute pain presenting to the pediatric emergency department. The investigators aim to describe the amount of pain reduction associated with intranasal hydromorphone, and to determine the optimal dose of intranasal hydromorphone associated with a clinically meaningful improvement in acute pain.

Description:

Primary Aim: Determine the change in pain intensity in children with moderate to severe pain who receive intranasal hydromorphone one hour after administration.

Secondary Aim(s): Describe the incidence of minor and major adverse events associated with intranasal hydromorphone in children with acute pain.

The investigators will assess the patient's pain at baseline (prior to study drug administration), then after study drug administration: 5 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, and then every 30 minutes thereafter until 6 hours; administration of non-protocolized rescue medication administration (i.e. administered after first two rescue doses of IN hydromorphone); or discharge from emergency department (whichever comes first). The pain score at 60 minutes will be the primary outcome.

The investigators will evaluate qualitative improvement in pain intensity at 15- and 30-minutes after study drug administration. If there is no improvement, or worsening of pain intensity, at each assessment, an additional rescue dose rescue dose of intranasal hydromorphone will be administered. After 60 minutes, the treating physician may administer any additional rescue medications at their discretion to treat the child's pain.

The patient will be assessed for minor and major adverse events for the duration of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: April 2018
• Est. primary completion date: April 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 17 Years

Eligibility

Inclusion Criteria:

• Age 4 to 17 years old, inclusive

• Moderate to severe pain (i.e. FPS-R or vNRS score of 4 or more)

• Requires parenteral opioid analgesic to treat their pain, as decided by treating physician

Exclusion Criteria:

• Allergy or known contraindication to receiving opioids

• Receipt of any opioid or benzodiazepine within preceding 6 hours

• Presence of intranasal obstruction that cannot be cleared readily

• Cannot speak English or Spanish

• Patient unlikely to be able to complete self-report measures of pain or questionnaires

• Known liver or kidney problems

• Currently critically ill

• Chronic pain condition (e.g. sickle cell disease, fibromyalgia)

Related Conditions & MeSH terms

• Acute Pain
• Pain

Intervention

Drug:
• Hydromorphone
To be administered by intranasal route using mucosal atomization device.

Locations

Country	Name	City	State
United States	Morgan Stanley Children's Hospital	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Columbia University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Tsze DS, Pan SS, DePeter KC, Wagh AM, Gordon SL, Dayan PS. Intranasal hydromorphone for treatment of acute pain in children: A pilot study. Am J Emerg Med. 2019 Mar 13. pii: S0735-6757(19)30162-7. doi: 10.1016/j.ajem.2019.03.013. [Epub ahead of print] — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Score on Faces Pain Scale - Revised	Pain was measured using the Faces Pain Scale - Revised (FPS-R). The FPS-R is a self-reported measure of pain that is administered using a picture of 6 different faces lined up in a row, each face representing an escalating degree of pain intensity. The faces, starting from the left-most face and moving towards the right-most face, are scored 0, 2, 4, 6, 8 and 10. A score of 0 represents no pain, a score of 10 represents "very much pain" (i.e. maximum possible pain). More information about the FPS-R can be found here: https://bit.ly/2VPk8GM	1 hour
Secondary	Number of Minor Adverse Events	Lightheadedness, dizziness; confusion; sleepy, drowsy, tiredness; nausea; vomiting; itchiness, warm sensation; dry mouth; bad taste in mouth; rhinitis.	6 hours
Secondary	Number of Major Adverse Events	Oxygen desaturation, respiratory depression, hypotension, bradycardia, need for supplemental oxygen, bag-mask ventilation, airway support intervention, administration naloxone.	6 hours
Secondary	Score on Verbal Numeric Rating Scale	Pain was measured using the Verbal Numerical Rating Scale (VNRS). The VNRS is a self-reported measure of pain that is administered verbally by asking a patient to rate their pain on a scale from 0 to 10, with 0 representing no pain, and 10 representing maximum pain. More information about the VNRS in children can be found here: https://bit.ly/2VZ7aWU	1 hour